Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CDXSBullishCorporate Developmentsnews

High materiality7/10

Codexis expands ECO Synthesis collaboration on stereo-defined siRNA fragments

Sep 28, 2026, 7:01 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Collaborations that advance proprietary manufacturing platforms can unlock longer-term cost and yield advantages, potentially expanding addressable markets for CDXS; however, no near-term revenue data is provided and outcome is data-dependent.

AI summary

What happened, with direct paths to the underlying reporting

Codexis announced a collaboration to evaluate stereo-defined oligonucleotide fragments produced with its ECO Synthesis platform, then assembled into siRNA duplexes by ligation. The project will compare enzymatically produced fragments to traditional SPOS in purity and product quality, following a TIDES USA 2026 showcase of stereocontrolled siRNA. Positive results could validate ECO Synthesis as a scalable manufacturing paradigm for RNAi therapeutics, potentially lowering costs and improving quality over time.

Codexis (CDXS) to test stereo-defined oligonucleotide fragments via ECO Synthesis with an unnamed siRNA innovator.
Fragments will be enzymatically produced and ligated into duplexes; SPOS comparison planned.
Work follows TIDES USA 2026 demo of full-length siRNA with phosphorothioate stereochemistry control (StereoSelect).
Aim: assess scalability, purity, and ligation performance for potential clinical development.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.